It didn’t take long for Terry Ross, former president and CEO of PACS firm Cemax-Icon, to find a new job. Ross, who left the Fremont, CA-based firm following the close of its acquisition by Eastman Kodak in December (SCAN 12/16/98), has been
It didnt take long for Terry Ross, former president and CEO of PACS firm Cemax-Icon, to find a new job. Ross, who left the Fremont, CA-based firm following the close of its acquisition by Eastman Kodak in December (SCAN 12/16/98), has been named president of ultrafast CT developer Imatron of South San Francisco, CA. He has served as an Imatron board member for 12 years.
Ross is the second Cemax-Icon executive to leave the company in recent months. Former vice president of sales and marketing Oran Muduroglu left the company in 1998 to head up Stentor, a San Francisco startup formed to commercialize dynamic transfer syntax (DTS), a protocol for low-cost enterprise-wide image distribution developed by a University of Pittsburgh Medical Center PACS research team. A DTS demonstration drew much attention in the infoRAD exhibit area at last years RSNA meeting.
Can Ultrasound-Based Radiomics Enhance Differentiation of HER2 Breast Cancer?
March 11th 2025Multicenter research revealed that a combined model of clinical factors and ultrasound-based radiomics exhibited greater than a 23 percent higher per patient-level accuracy rate for identifying HER2 breast cancer than a clinical model.